Society News

FDA Draft Guidance on DCT for drugs, biological products and devices - SCDM comments

Society for Clinical Data Management (SCDM) > Latest News > Society News > FDA Draft Guidance on DCT for drugs, biological products and devices – SCDM comments
  • Society for Clinical Data Management
  • No Comments

FDA Draft Guidance on DCT for drugs, biological products and devices – SCDM comments

Join forces with your SCDM colleagues and have your say on decentralized trial guidance! Public comments are currently open for the Decentralized Clinical Trials for Drugs, Biological Products, and Devices publication. SCDM is committed to supporting its community in this important endeavour by gathering comments from a diverse range of industry professionals. This is your chance to actively contribute to shaping regulatory policies, potentially influencing the final guidelines that govern decentralized trials. Don’t miss out on this opportunity—submit your application today and make a difference!

Author: Society for Clinical Data Management
Contact Us